Edison has published a comprehensive report examining the investment merits of Transgene, focusing on the potential of its four lead immunotherapy products for various cancers and infectious diseases, including hepatitis C. The report is timely because of the increased interest in immunotherapies to treat cancers after the approvals of Dendreon’s Provenge and Bristol-Myers Squibb’s Yervoy, and activity in the hepatitis C field following recent acquisitions by Roche, Gilead and Bristol-Myers Squibb.
The launch of coverage on Transgene is part of a programme of research initiations on biotech companies worldwide. Edison covers over 65 biotech companies in Europe, North America and Australia. Its biotech research team has a particular focus on companies active in the area of oncology with 15 companies now under active coverage.
Edison has pioneered a scientific detail-oriented approach to analysing companies in the biotech sector that aims to inform investors while providing a realistic assessment of the competitive strengths and threats to key drug development programmes. All facts are carefully sourced and the analysis is underpinned by rigorous financial models. Edison’s reports provide an overall company valuation without any specific stock recommendation or target price.